Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Expert opinions in nuclear medicine: Finding the “holy grail” in infection imaging
Published in: Frontiers in Medicine
Access to document
10.3389/fmed.2023.1149925
document
Nuclear medicine imaging techniques are now widely accepted and increasingly used for diagnosing and treatment monitoring of infectious and inflammatory diseases. The latter has been exemplified by numerous recent clinical guidelines in which PET imaging is now part of the diagnostic flowcharts. In this perspective paper we discuss the current available guidelines, the current limitations, and we provide the future aims of research to achieve the holy grail in nuclear medicine: the differentiation between infection, inflammation and malignancy.
Andor W J M Glaudemans, Olivier Gheysens
Added Value of Abnormal Lymph Nodes Detected with FDG-PET/CT in Suspected Vascular Graft Infection
Published in: Biology
Access to document
10.3390/biology12020251
document
Vascular graft and endograft infections (VGEI) cause a serious morbidity and mortality burden. 18F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18F-FDG PET/CT) imaging is frequently used in the diagnostic workup, but the additional value of abnormal ( 18F-FDG active and/or enlarged) locoregional lymph nodes is unknown. In this retrospective study, the additional diagnostic value of abnormal locoregional lymph nodes on 18F-FDG PET/CT imaging for VGEI was evaluated, including 54 patients with a culture-proven VGEI (defined according to the Management of Aortic Graft Infection [MAGIC] group classification) and 25 patients...
Nick D. van Rijsewijk, Jasper H.G. Helthuis, Andor W.J.M. Glaudemans, Marjan Wouthuyzen-Bakker, Niek H.J. Prakken, David J. Liesker, Ben R. Saleem, Riemer H.J.A. Slart
Molecular imaging as biomarker for treatment response and outcome in breast cancer
Published in: Therapeutic advances in medical oncology
Access to document
10.1177/17588359231170738
document
Molecular imaging, such as positron emission tomography (PET), is increasingly used as biomarker to predict and assess treatment response in breast cancer. The number of biomarkers is expanding with specific tracers for tumour characteristics throughout the body and this information can be used to aid the decision-making process. These measurements include metabolic activity using [ 18F]fluorodeoxyglucose PET ([ 18F]FDG-PET), oestrogen receptor (ER) expression using 16α-[ 18F]Fluoro-17β-oestradiol ([ 18F]FES)-PET and human epidermal growth factor receptor 2 (HER2) expression using PET with radiolabelled trastuzumab (HER2-PET). In early breast cancer, baseline...
Jasper J L van Geel, Erik F J de Vries, Michel van Kruchten, Geke A P Hospers, Andor W J M Glaudemans, Carolina P Schröder
Ultra-low dose infection imaging of a newborn without sedation using long axial field-of-view PET/CT
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-022-05979-3
document
N D van Rijsewijk, B van Leer, O V Ivashchenko, E H Schölvinck, F van den Heuvel, J H van Snick, R H J A Slart, W Noordzij, A W J M Glaudemans
Long Axial Field-of-View PET for Ultra-Low-Dose Imaging of Non-Hodgkin Lymphoma during Pregnancy
Published in: Diagnostics
Access to document
10.3390/diagnostics13010028
document
Generally, positron emission tomography imaging is not often performed in the case of pregnant patients. The careful weighing of the risks of radiation exposure to the fetus and benefits for cancer staging and the swift onset of treatment for the mother complicates decision making in clinical practice. In oncology, the most commonly used PET radiotracer is 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG), a glucose analog which has established roles in the daily routines for, among other applications, initial diagnosis, staging, (radiation) therapy planning, and response monitoring. The introduction of long axial...